Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-RAD51 Antibody (R3R35)

Catalog #:   RHG09805 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2b
Applications: IP, WB
Accession: Q06609
Overview

Catalog No.

RHG09805

Species reactivity

Human

Host species

Mouse

Isotype

IgG2b

Clonality

Monoclonal

Tested applications

IP: 1:100-1:200, WB: 1:500-1:1000

Target

HsRAD51, RAD51A, RECA, hRAD51, RAD51, RAD51 homolog A, DNA repair protein RAD51 homolog 1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q06609

Applications

IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3R35

Data Image
  • Immunoprecipitation
    Lane 1: Jurkat lysate ; Lane 2: RAD51 immunoprecipitated from Jurkat lysate by RHG09805;Lane 3: The same as Lane 2 but use IgG isotype control antibody ;Result: RHG09805 can immunoprecipitate RAD51;
  • Western blot
    Western blot analysis using RAD51 mouse mAb against Jurkat lysate
References

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients., PMID:40456663

The influence of homologous recombination repair on temozolomide chemosensitivity in gliomas., PMID:40120126

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence., PMID:39914385

Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition., PMID:39352803

Atrial fibrillation recurrence after catheter ablation is associated with RAD51 and p63 proteins., PMID:38988509

KIN17 functions in DNA damage repair and chemosensitivity by modulating RAD51 in hepatocellular carcinoma., PMID:38935235

Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair., PMID:38383600

Photonic Crystal Surface Mode Real-Time Imaging of RAD51 DNA Repair Protein Interaction with the ssDNA Substrate., PMID:38248420

Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs., PMID:37655260

Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes., PMID:37541687

Inhibition of p53 and ATRX increases telomeric recombination in primary fibroblasts., PMID:37499040

Three-color dSTORM Imaging and Analysis of Recombination Foci in Mouse Spread Meiotic Nuclei., PMID:37497444

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis., PMID:36564284

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial., PMID:36156447

Dynamics of DNA damage response markers, RAD51 and XRCC1, throughout the menstrual cycle and pregnancy in healthy women. Increment during pregnancy and relation to a low titer of antinuclear antibodies., PMID:35816185

Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry., PMID:35628514

The RNA-binding protein La/SSB associates with radiation-induced DNA double-strand breaks in lung cancer cell lines., PMID:34636174

Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification., PMID:34342091

Reproductive Isolation Between Taxonomically Controversial Forms of the Gray Voles (Microtus, Rodentia; Arvicolinae): Cytological Mechanisms and Taxonomical Implications., PMID:34040633

In search for biomarkers and potential drug targets for uterine serous endometrial cancer., PMID:33754208

Kinase CDK2 in Mammalian Meiotic Prophase I: Screening for Hetero- and Homomorphic Sex Chromosomes., PMID:33671248

Impact of hypoxia on the double-strand break repair after photon and carbon ion irradiation of radioresistant HNSCC cells., PMID:33288855

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer., PMID:33196706

Detection of DSBs in C. elegans Meiosis., PMID:32840787

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment., PMID:32778095

Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma., PMID:32653671

CDK5 Activates Hippo Signaling to Confer Resistance to Radiation Therapy Via Upregulating TAZ in Lung Cancer., PMID:32407930

[Hereditary breast carcinomas pathologist's perspective]., PMID:32241645

Abnormal expression of p-ATM/CHK2 in nasal extranodal NK/T cell lymphoma, nasal type, is correlated with poor prognosis., PMID:32220941

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma., PMID:32060401

Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report., PMID:31865638

A Novel Cell-Penetrating Antibody Fragment Inhibits the DNA Repair Protein RAD51., PMID:31375703

Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility., PMID:31347298

Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells., PMID:30863489

Analysis of S100A11 in DNA Damage Repair., PMID:30710290

FKBP25 participates in DNA double-strand break repair., PMID:30620620

ATR-Mediated Global Fork Slowing and Reversal Assist Fork Traverse and Prevent Chromosomal Breakage at DNA Interstrand Cross-Links., PMID:30184498

A cell-penetrating antibody inhibits human RAD51 via direct binding., PMID:29036688

Silver nanoparticles coupled to anti‑EGFR antibodies sensitize nasopharyngeal carcinoma cells to irradiation., PMID:28990103

Meiotic Recombination in the Giraffe (G. reticulata)., PMID:28723680

Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes., PMID:28461573

Chromatin organization revealed by nanostructure of irradiation induced γH2AX, 53BP1 and Rad51 foci., PMID:28094292

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial., PMID:27884140

Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells., PMID:27630154

MAR-Mediated transgene integration into permissive chromatin and increased expression by recombination pathway engineering., PMID:27575535

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib., PMID:27702817

Mapping Recombination Initiation Sites Using Chromatin Immunoprecipitation., PMID:27511175

Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model., PMID:27467592

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance., PMID:27454289

Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts., PMID:27196891

Datasheet

Document Download

Anti-RAD51 Antibody (R3R35).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-RAD51 Antibody (R3R35) [RHG09805]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only